We are live on ! Find out more
ITOS

iTeos Therapeutics
ITOS

Delisted

ITOS was delisted on the 28th of August, 2025.

Back to rankings

137 hedge funds and large institutions have $396M invested in iTeos Therapeutics in 2023 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 48 increasing their positions, 39 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

23% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 39

1.81% more ownership

Funds ownership: 99.18% → 100.99% (+1.8%)

2% more capital invested

Capital invested by funds: $389M → $396M (+$7.2M)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

5% less funds holding

Funds holding: 144 → 137 (-7)

14% less first-time investments, than exits

New positions opened: 31 | Existing positions closed: 36

86% less call options, than puts

Call options by funds: $2.04M | Put options by funds: $14.1M

Holders
137
Holders Change
-7
Holders Change %
-4.86%
% of All Funds
2%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
31
Increased
48
Reduced
39
Closed
36
Calls
$2.04M
Puts
$14.1M
Net Calls
-$12M
Net Calls Change
-$16.3M

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$19.8M
2
EC
EcoR1 Capital
California
+$11.1M
3
Renaissance Technologies
Renaissance Technologies
New York
+$3.02M
4
Citigroup
Citigroup
New York
+$2.56M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$1.91M

Top Sellers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
-$10.2M
2
BlackRock
BlackRock
New York
-$7.82M
3
CS
Candriam SCA
Luxembourg
-$5.6M
4
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$5.48M
5
Vanguard Group
Vanguard Group
Pennsylvania
-$3.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
Susquehanna International Group
26
Susquehanna International Group
Pennsylvania
$3.12M +$1.91M +192,592 +208%
Northern Trust
27
Northern Trust
Illinois
$2.81M -$202K -20,385 -7%
SAM
28
Sectoral Asset Management
Quebec, Canada
$2.41M +$644K +64,981 +42%
Vontobel Holding
29
Vontobel Holding
Switzerland
$2.41M +$644K +64,981 +42%
Charles Schwab
30
Charles Schwab
California
$2.21M -$85.5K -8,621 -4%
N
31
Nuveen
North Carolina
$2.12M +$1.32M +133,501 +223%
D.E. Shaw & Co
32
D.E. Shaw & Co
New York
$1.77M +$472K +47,600 +42%
RAM
33
Readystate Asset Management
Illinois
$1.55M +$358K +36,100 +34%
Fidelity Investments
34
Fidelity Investments
Massachusetts
$1.55M +$8.71K +879 +0.6%
CSS
35
Cubist Systematic Strategies
Connecticut
$1.47M +$1.2M +120,925 +925%
AG
36
Algert Global
California
$1.41M +$324K +32,680 +34%
PAM
37
Panagora Asset Management
Massachusetts
$1.36M -$216K -21,765 -15%
Bank of New York Mellon
38
Bank of New York Mellon
New York
$1.36M -$1.53M -154,808 -55%
BCM
39
Bridgeway Capital Management
Texas
$1.33M -$551K -55,580 -31%
EF
40
Empowered Funds
Pennsylvania
$1.33M +$108K +10,920 +10%
SPS
41
Susquehanna Portfolio Strategies
Pennsylvania
$1.13M +$1.02M +103,120 New
Squarepoint
42
Squarepoint
New York
$1.1M +$749K +75,591 +300%
DCM
43
DAFNA Capital Management
California
$1.08M – – –
AQR Capital Management
44
AQR Capital Management
Connecticut
$1.03M +$343K +34,620 +58%
Group One Trading
45
Group One Trading
Illinois
$939K +$850K +85,728 New
Qube Research & Technologies (QRT)
46
Qube Research & Technologies (QRT)
United Kingdom
$906K +$821K +82,781 New
Victory Capital Management
47
Victory Capital Management
Texas
$874K -$192K -19,340 -20%
Massachusetts Financial Services
48
Massachusetts Financial Services
Massachusetts
$831K -$23.8K -2,397 -3%
BFM
49
Boothbay Fund Management
New York
$829K +$17.1K +1,720 +2%
Ameriprise
50
Ameriprise
Minnesota
$796K -$600K -60,499 -45%
1
2
3 4 5

ITOS Hedge Fund Activity: Q4 2023 in Review

137 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in iTeos Therapeutics (ITOS) for Q4 2023, worth a combined $396M — up 1.9% from $389M a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of ITOS and 31 opened new positions — a net loss of 5 holders — while 39 trimmed existing stakes and 48 added.

The largest buyer was Morgan Stanley, adding an estimated $19.8M. The largest seller was State Street, cutting an estimated $10.2M.

  • 137 institutional investors held iTeos Therapeutics (ITOS) as of Q4 2023, down from 144 in Q3 2023.
  • Funds reported $396M of iTeos Therapeutics stock for Q4 2023, up 1.9% quarter-over-quarter.
  • 31 funds opened new iTeos Therapeutics positions in Q4 2023 and 36 closed out, a net change of -5 holders.
  • The largest iTeos Therapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $19.8M added.
  • The largest iTeos Therapeutics seller in Q4 2023 was State Street, an estimated $10.2M sold.

Based on aggregated 13F filings for Q4 2023.